Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-341 in multiple system atrophy
2023-509876-40-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in multiple system atrophy (MSA) comparing TAK-341 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 52 on modified UMSARS Part I. Started Sep 2024; status: completed.
02
Drugs
MEDI1341
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2023-509876-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509876-40-00.